Prospective clinical observation of Mediation of Zhongzhou Prescription in the treatment of obese polycystic ovary syndrome with insulin resistance
PANG Ying1 LIU Jinfeng2 JIANG Zixi3 LIU Yuxin3 TANG Lei3 ZHU Xiujuan3 WANG Guohua3 LIU Yanfeng1
1.Department of Gynecology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China;
2.Department of Traditional Chinese Medicine, Dongfeng Health Service Center of Chaoyang District, Beijing 100025, China;
3.Department of Gynecology, the Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing 100029, China
Abstract：Objective To explore the clinical effect and security of the empirical formula of Professor Wang Guohua, Mediation of Zhongzhou Prescription, in the treatment of obese polycystic ovary syndrome (PCOS) with insulin resistance. Methods A total of 59 PCOS patients with insulin resistance and obesity with syndrome of phlegm-dampness due to spleen deficiency in the Gynecology Department of the Third Affiliated Hospital of Beijing University of Chinese Medicine from September 2016 to March 2018 were selected as the research subjects. Patients were divided into control group (29 cases) and experimental group (30 cases) according to the random number table method. Metformin Tablets were taken orally in the control group, Mediation of Zhongzhou Prescription were taken orally in the experimental group. Basal body temperature (BBT) was recorded daily during treatment. Body mass index (BMI), waist-to-hip ratio (WHR), homeostasis model assessment-insulin resistance (HOMA-IR) and testosterone (T), luteinizing hormone/follicle-stimulating hormone (LH/FSH) were measured before and after treatment. The clinical efficacy of the two groups was compared before and after treatment, and the occurrence of adverse reactions was observed. Results After treatment, the total effective rate of clinical syndromes in the experimental group was higher than that in the control group (P ＜ 0.05). Before treatment, there were no significant differences in WHR, BMI, HOMA-IR indexes and sex hormone (T, LH and FSH) levels between the two groups (P ＞ 0.05). After treatment, in the experimental group, the levels of WHR, BMI, HOMA-IR and LH/FSH were significantly lower than before treatment (P ＜ 0.05), in the control group, the levels of BMI and HOMA-IR were significantly lower than before treatment (P ＜ 0.05), and LH/FSH in the experimental group was lower than that in the control group (P ＜ 0.05). There were four cases of gastrointestinal reactions in control group, while no obvious adverse reactions occurred in treatment group. Conclusion Professor Wang Guohua′s empirical formula in the treatment of obese PCOS with insulin resistance has significant effect and certain clinical application value, which is worthy of promotion, application and further research.
庞颖1 刘金凤2 江紫曦3 刘雨昕3 唐磊3 朱秀娟3 王国华3 刘雁峰1. 斡旋中州方治疗肥胖型多囊卵巢综合征伴胰岛素抵抗的前瞻性临床观察[J]. 中国医药导报, 2020, 17(26): 124-128.
PANG Ying1 LIU Jinfeng2 JIANG Zixi3 LIU Yuxin3 TANG Lei3 ZHU Xiujuan3 WANG Guohua3 LIU Yanfeng1. Prospective clinical observation of Mediation of Zhongzhou Prescription in the treatment of obese polycystic ovary syndrome with insulin resistance. 中国医药导报, 2020, 17(26): 124-128.
[1] 潘雪，刘雁峰，梁嘉玲，等.多囊卵巢综合征与心理应激的相关性研究进展[J].中国妇幼保健，2019，34（21）：5078-5081.
[2] 乔杰，李蓉，李莉，等.多囊卵巢综合征流行病学研究[J].中国实用妇科与产科杂志，2013，29（11）：849-852.
[3] 宋颖，李蓉.多囊卵巢综合征中国诊疗指南解读[J].实用妇产科杂志，2018，34（10）：737-741.
[4] Rong L，Zhang QF，Yang DZ，et al． Prevalence of poly-cystic ovary syndrome in women in China：A Large Community-Based Study [J]. Hum Reprod，2013，28（9）：2562-2569.
[5] 曾杰，罗国贤，区林伟，等.二甲双胍联合炔雌醇环丙孕酮片治疗多囊卵巢综合征的临床效果观察[J].临床合理用药杂志，2019，12（35）：77-78.
[6] 李砚，王运萍，姚念玲，等.达英-35联合二甲双胍治疗多囊卵巢综合征对患者性激素、胰岛素抵抗的影响[J].海南医学，2019，30（17）：2203-2205.
[7] 宋锐，苗辉.二甲双胍在治疗多囊卵巢综合征中对性激素、抑制素、激活素及胰岛素样生长因子的影响研究[J].湖南师范大学学报：医学版，2019，16（5）：119-122.
[8] 曹泽毅.中华妇产科学[M].北京：人民卫生出版社，2014.
[9] 林金芳，李昕，朱铭伟.多囊卵巢综合征的分型探讨[J].中华妇产科杂志，2006，41（10）：684-688.
[10] 中华人民共和国卫生部疾病控制司.中国成人超重和肥胖症预防控制指南[M].北京：人民卫生出版社，2006.
[11] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002.
[12] Saddick SY. Identifying Genes Associated with the Development of Human Polycystic Ovary Syndrome [J]. Saudi J Biol Sci, 2020，27（5）：1-9.
[13] 傅山.傅青主女科[M].北京：人民卫生出版社，2006.
[14] 姚兆敏，陈卫东，仰忠华，等.白术研究进展及其质量标志物（Q-marker）的预测分析[J].中草药，2019，50（19）：4796-4807.
[15] 王晶，张世洋，盛永成，等.白术治疗胃肠道疾病药理作用研究进展[J].中华中医药学刊，2018，36（12）：2854-2858.
[16] 张晓娟，左冬冬.白术化学成分及药理作用研究新进展[J].中医药信息，2018，35（6）：101-106.
[17] 李会英，赵晓丽，王丽，等.川陈皮素对高糖诱导的大鼠肾小球系膜细胞炎症因子和氧化应激水平的影响[J].中国新药杂志，2019，28（20）：2537-2542.
[18] 庞颖，王国华，刘金凤，等.王国华教授从斡旋中州入手治疗多囊卵巢综合征伴胰岛素抵抗的经验探讨[J].中国当代医药，2018，25（12）：104-107.
[19] Laakso M，Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development [J]. Nat Rev Endocrinol，2014，10（5）：293-302.
[20] Bastien M，Poirier P，Lemieux I，et al. Overview of epidemiology and contribution of obesity to cardiovascular disease [J]. Prog Cardiovasc Dis，2014，56（4）：369-381.
[21] Shea JL，King MT，Yi Y，et al. Body fat percentage is associated with cardiometabolic dysregulation in BMI-defined normal weight subjects [J]. Nutr Metab Cardiovasc Dis，2012，22（9）：741-747.
[22] Peng Z，Rui W，Chunshi G，et al. Prevalence of Central Obesity among Adults with Normal BMI and Its Association with Metabolic Diseases in Northeast China [J]. Plos One，2016，11（7）：e0160402.
[23] 周琴，李永强，祝爽爽，等.非糖尿病人群腰臀比和慢性肾脏病的相关性[J].南方医科大学学报，2016，36（9）：1221-1225.
[24] Kuba VM，Leone C，Damiani D. Is waist-to-height ratio a useful indicator of cardio-metabolic risk in 6-10-year-old children [J]. BMC Pediatr，2013，13：91.
[25] 杨兴燕，邵孟佼，周琴，等.非糖尿病正常体质量人群的腰臀比与胰岛素抵抗的相关性[J].南方医科大学学报，2017，37（11）：1540-1544.
[26] 岳瑶函，赵嘉晶，汪颖珏.多囊卵巢综合征不同中医证型与糖脂代谢水平及性激素水平差异性分析[J].四川中医，2018，36（1）：78-81.
[27] 朱华东，张晓丽，陈晨，等.不同腰臀比的多囊卵巢综合征患者代谢指标分析[J].安徽医药，2016，20（8）：1548-1550.
[28] Sanchez-Garrido MA，Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome：pathogenic role of androgen excess and potential therapeutic strategies [J]. Mol Metab，2020，35：100937.
2020, Vol. 17 
京公网安备 11010502046598号